Operating CF
$4.34B
Capex
-$899M
Free Cash Flow
$3.44B
FCF Margin
+79.3%
Cash flow waterfall for Boston Scientific (BSX) — TTM through Q1 2026
Free cash flow: $3.44B
Cash flow breakdown for Boston Scientific (BSX) — TTM through Q1 2026
| Line item | Amount | Running total |
|---|---|---|
| Operating Cash Flow | $4.34B | $4.34B |
| Capital Expenditure | -$899M | $3.44B |
| Free Cash Flow | $3.44B | $3.44B |
| Acquisitions | -$1.88B | $1.57B |
| Other Investing | $45M | $1.61B |
| Net Debt Change | -$997M | $613M |
| Other Financing & FX | $90M | $703M |
| Net Cash Increase | $703M | $703M |
- Operating Cash Flow$4.34B
- Capital Expenditure-$899M
- Free Cash Flow$3.44B
- Acquisitions-$1.88B
- Other Investing$45M
- Net Debt Change-$997M
- Other Financing & FX$90M
- Net Cash Increase$703M
Want to see what drove the FCF change?Free Cash Flow Bridge
Frequently asked questions
Data & methodology
Boston Scientific (BSX) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Cash Flow
Forecast & Valuation
Operations
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement
Capital Return
How this company returns cash to shareholders — buybacks, dividends, and stock splits.